A Fulminant Hepatic Failure Model in the Rat

The development of a fulminant hepatic failure (FHF) model is necessary for evaluating the efficacy of extracorporeal liver support systems. Recognizing the multifaceted functions of the liver, including synthesis and degradation, we investigated blood chemistry, histological findings, and survival rate in d-galactosamine (GalN)-intoxicated rats. The pathophysiologic response of inflammatory cytokines, interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), was also measured. Sprague-Dawley rats (200–300 g) were divided into two groups: GalN and saline injection. Rats were killed at 1, 3, 6, 12, 24, 36, 48, 72, and 168 hr after intraperitoneal injection of GalN (1.4 g/kg) or saline. In both groups, liver-specific markers, liver histology, and IL-1β and TNF-α levels in blood and liver tissue were analyzed. In a second series of experiments, the survival rates were examined after two administrations of GalN at 1.0, 1.4 or 2.0 g/kg, at a 12-hr interval. In the GalN injection group, the liver-specific markers reached peak levels between 36 and 48 hr after injection. Histologically, hepatocellular necrosis was seen at 6–48 hr, followed by a regenerative phase occurring between 72 and 168 hr. IL-1β and TNF-α levels in liver tissue peaked at 12 hr and 1 hr, respectively. The levels of these cytokines in blood, however, did not change significantly. The survival rates at day 7 for 1.0, 1.4 or 2.0 g/kg GalN injected twice were 77.8%, 16.7%, and 0%, respectively. These results suggest that single and double injection of GalN enable the development of reversible and irreversible FHF models. The results also indicate that IL-1β and TNF-α are useful markers of liver injury.

[1]  S. Sabesin,et al.  D-Galactosamine Hepatitis I. Hepatocellular Injury and Fatty Liver Following A Single Dose , 1971 .

[2]  D. Keppler,et al.  Galactosamine induced liver injury. , 1972, Progress in liver diseases.

[3]  T. Chang,et al.  Biochemical, hematological and histological changes in a fulminant hepatic failure rat model for artificial liver assessment. , 1979, Artificial organs.

[4]  D. Samuel,et al.  Orthotopic Liver Transplantation in Fulminant and Subfulminant Hepatitis The Paul Brousse Experience , 1995, Annals of surgery.

[5]  L. Flendrig,et al.  Semipermeable hollow fiber membranes in hepatocyte bioreactors: a prerequisite for a successful bioartificial liver? , 2008, Artificial organs.

[6]  R. Strieter,et al.  Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. , 1989, Science.

[7]  J. Ljubimova,et al.  Fulminant hepatic failure in rats: Survival and effect on blood chemistry and liver regeneration , 1996, Hepatology.

[8]  J. Fierer,et al.  D-Galactosamine hepatotoxicity is associated with endotoxin sensitivity and mediated by lymphoreticular cells in mice. , 1985, Gastroenterology.

[9]  Regional cerebral edema and chloride space in galactosamine‐induced liver failure in rats , 1997, Hepatology.

[10]  M B Furie,et al.  Migration of neutrophils across endothelial monolayers is stimulated by treatment of the monolayers with interleukin-1 or tumor necrosis factor-alpha. , 1989, Journal of immunology.

[11]  F. Cerra,et al.  Gel-entrapment bioartificial liver therapy in galactosamine hepatitis. , 1995, The Journal of surgical research.

[12]  A. Morelli,et al.  Interleukin 10 reduces lethality and hepatic injury induced by lipopolysaccharide in galactosamine-sensitized mice. , 1996, Gastroenterology.

[13]  Y. Shiratori,et al.  Modulation of hepatotoxicity by macrophages in the liver , 1988, Hepatology.

[14]  F. Cerra,et al.  An anesthetized model of lethal canine galactosamine fulminant hepatic failure , 1995, Hepatology.

[15]  L. Blendis,et al.  Reversal of experimental acute hepatic failure in the rat. , 1980, The Journal of surgical research.

[16]  C. Dinarello,et al.  Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. , 1991, The Journal of clinical investigation.

[17]  T. Chang,et al.  Brain edema and the blood brain barrier in galactosamine-induced fulminant hepatic failure rats. An animal model for evaluation of liver support systems. , 1990, ASAIO transactions.

[18]  M. Leist,et al.  Tumor necrosis factor-induced hepatic DNA fragmentation as an early marker of T cell-dependent liver injury in mice. , 1995, Gastroenterology.

[19]  D. Samuel,et al.  Liver transplantation in fulminant and subfulminant hepatitis , 1989 .

[20]  S. Seki,et al.  Effects of putrescine on D‐galactosamine–induced acute liver failure in rats , 1990, Hepatology.

[21]  T. Yoshida,et al.  Endotoxin‐induced cytokine gene expression and excretion in the liver , 1994, Hepatology.

[22]  J. Terblanche,et al.  Animal models of fulminant hepatic failure , 1991, Digestive diseases and sciences.

[23]  M. Kitajima,et al.  Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat. , 1997, Transplantation.

[24]  D. V. van Thiel,et al.  A dog model for acetaminophen-induced fulminant hepatic failure. , 1989, Gastroenterology.

[25]  A. Demetriou,et al.  Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. , 1997, Annals of surgery.

[26]  M. Leist,et al.  Interleukin‐1 and nitric oxide protect against tumor necrosis factor α‐induced liver injury through distinct pathways , 1995, Hepatology.

[27]  Y. Shiratori,et al.  Role of polymorphonuclear leukocytes in galactosamine hepatitis: Mechanism of adherence to hepatic endothelial cells , 1994, Hepatology.

[28]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[29]  K. Maezono,et al.  Effect of alanine on D‐galactosamine‐induced acute liver failure in rats , 1996, Hepatology.

[30]  K. Soo,et al.  An improved model of galactosamine-induced fulminant hepatic failure in the pig. , 1999, The Journal of surgical research.

[31]  C. Lowenstein,et al.  Impaired liver regeneration in inducible nitric oxide synthasedeficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.